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Abstract 
Meta-analyses and mendelian randomization(MR) may clarify the associations of smoking, 
blood cells, and myeloproliferative neoplasms(MPN). We investigated the association of 
smoking with blood cells in the Danish General Suburban Population Study(GESUS,N=11,083), 
meta-analyses(including GESUS) of 92 studies(N=531,741), and MR of smoking variant 
CHRNA3(rs1051730[A]) in UK Biobank, and with MPN in a meta-analysis of 6 
studies(N(total/cases):1,425,529/2187), totaling 2,307,745 participants.  
In the meta-analysis the random effects SMD in current smokers vs. non-smokers was 0.82(0.75-
0.89,p=2.0*10-108) for leukocytes, 0.09(-0.02-0.21,p=0.12) for erythrocytes, 0.53(0.42-
0.64,p=8.0*10-22) for haematocrit, 0.42(0.34-0.51,p=7.1*10-21) for haemoglobin, 0.19(0.08-
0.31,p=1.2*10-3) for MCH, 0.29(0.19-0.39,p=1.6*10-8) for MCV, and 0.04(-0.04-0.13,p=0.34) 
for platelets with trends for ever/ex-/current smokers, light/heavy smokers, and female/male 
smokers. Analyses presented high heterogeneity but low publication bias. Per allele in CHRNA3, 
cigarettes per day in current smokers were associated with increased blood cell counts 
(leukocytes, neutrophils), MCH, RDW, and MCV. Pooled fixed effects OR for MPN was 
1.44(95%CI:1.33-1.56;p=1.8*10-19;I2=0%) in current smokers, 1.29(1.15-1.44;p=8.0*10-
6;I2=0%) in ex-smokers, 1.49(1.26-1.77;p=4.4*10-6;I-square=0%) in light-smokers, and 
2.04(1.74-2.39,p=2.3*10-18;I2=51%) in heavy-smokers compared with non-smokers. Smoking is 
observationally and genetically associated with blood cell counts in current and ex-smokers and 
observationally with risk of MPN.  
 
Keywords:  
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Abbreviations (in alphabetic order): 
CBC: Complete blood count   
ET: Essential thrombocytaemia  
GESUS: The Danish General Suburban Population Study 
HCT: Haematocrit  
Hgb: Haemoglobin  
IRF: Immature reticulocyte fraction 
MCH: Mean corpuscular haemoglobin 
MCHC: Mean corpuscular haemoglobin concentration  
MCV: Mean corpuscular volume  
MF: Myelofibrosis  
MPN: Myeloproliferative neoplasms 
MPV: Mean platelet volume 
MRV: Mean reticulocyte volume 
NLR: Neutrophil lymphocyte ratio 
PCT: Platelet crit 
PDW: Platelet distribution width  
PLT: Platelet 
PV: Polycytaemia vera 
RBC: Red blood cell 
RDW: Red blood cell distribution width (CV: Coefficient of variation (%)) 
WBC: White blood cell 
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Introduction  
The classic Philadelphia-negative chronic myeloproliferative neoplasms (MPN) are acquired 
stem cell diseases that include essential thrombocytaemia (ET), polycytaemia vera (PV), primary 
myelofibrosis (MF) and unclassifiable MPN (MPN-U)(Spivak 2017). Patients with MPN have an 
increased comorbidity burden and exhibit shorter survival compared to the general 
population(Hultcrantz, et al 2015). Chronic inflammation may be a driving force for clonal 
evolution and disease progression from the early cancer stage with elevated cell counts (ET, 
early prefibrotic myelofibrosis, PV) to the advanced burnt-out phase with severe myelofibrosis 
(Campbell, et al 2005, Frederiksen, et al 2011, Hasselbalch 2012, Hasselbalch and Bjorn 2015, 
Larsen, et al 2007).  
 Smoking associated toxic substances in tobacco are highly potent inflammatory stimuli 
and associated with tumorigenesis and clonal hematopoiesis (Hasselbalch 2015). Smoking 
associates with increased blood cells(Billimoria, et al 1975, Dotevall, et al 1987, Eisenga, et al 
2018, Lao, et al 2009, Lowe, et al 1992, Parry, et al 1997, Smith, et al 2003, Wannamethee, et al 
2005) (full list of references in Supplementary Material) and MPN (Kroll, et al 2012, Leal, et al 
2014, Lindholm Sorensen and Hasselbalch 2016, Pasqualetti, et al 1997, Pedersen, et al 2018) in 
some but not all observational studies, likely due to differences in study size, effect size and 
direction, year published, sex and age distribution, geographical region, smoking status (current 
vs. ex-smoker), smoking duration, smoking intensity (heavy vs. light), and ethnicity. Smoking 
and MPNs share several clinical and biochemical characteristics including a high risk of 
thrombosis, partly explained by an elevated haematocrit and leukocytosis and in vivo leukocyte, 
platelet and endothelial activation (Hasselbalch 2015). Yet, no previous meta-analyses of 
smoking, differences in complete blood counts (CBC), and MPN have been published.  
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 As observational studies may be prone to reverse causation, the genome-wide association 
(GWAS) SNP CHRNA3 (The Cholinergic Receptor Nicotinic Alpha 3 Subunit, rs1051730 [A]), 
which associates with number of cigarettes smoked per day(Tobacco and Genetics 2010) 
(Pedersen, et al 2019) may provide an opportunity to assess associations to CBC through an 
instrumental variable approach termed Mendelian Randomization (MR).  
We investigated the association of cigarette smoking with CBC in a Danish observational study 
(N=11,083), meta-analyses of 92 studies (N=531,741), and MR analysis of CHRNA3 in 
UKbiobank (N=350,475), and the association of smoking with MPN in a meta-analysis of 6 
studies (N=1,425,529), totaling 2,307,745 participants. 
 
Methods  
The Danish General Suburban Population Study (GESUS) is a cross-sectional general population 
study of 21,205 adults (participation rate 43%) from 2010-2013(Bergholdt, et al 2013, Cordua, et 
al 2019). We included 11,083 healthy participants (mean age was 52 years (SD: 12), 53.5% 
women) with no cardiovascular disease or cancer. CBC were measured on fresh EDTA whole 
blood on Sysmex XE-5000 within 24h of blood draw. We calculated adjusted means for CBC by 
smoking status  (never, current, ex-, and ever smoker) from multivariable linear regression 
models adjusted for potential confounders that a priori could be associated with tobacco smoking 
and/or blood cell values (Supplementary methods).  
The meta-analysis protocol was registered at the International Prospective Register of 
Systematic Reviews (Prospero), https://www.crd.york.ac.uk/PROSPERO/, 
CRD42018102571(Page, et al 2018). A systemic literature search with assistance from 
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Countway Library at Harvard Medical School was conducted on the databases Pubmed, 
EMBASE, Web of Science and World Health Organisation Global Health Library for all relevant 
papers published on smoking, complete blood cell count indices, and myeloproliferative 
neoplasms until June 11th, 2018 (Supplementary methods). An article was relevant if it 
originated from cross-sectional, case control, retrospective, population, prospective, or trial 
studies at baseline and reported original data on CBC or MPN. For CBC, we calculated the 
pooled effect size using the unitless standardized mean difference (SMD, 95% CI) and the 
pooled non-standardized (weighted) mean differences (WMD, 95% CI). For CBC, we used the 
random-effects model (DerSimonian and Laird) due to heterogeneity. For MPN, we calculated 
the fixed effects pooled odds ratio (95% CI) as there was no study heterogeneity. Heterogeneity, 
sensitivity analyses, and publication bias are described in Supplementary Methods. We 
assessed double-sided p-values with Bonferroni correction for multiple comparisons by dividing 
the p-values with 24 cell type measurements to obtain an overall global significance of double-
sided p<0.002.  
We used instrumental variable analysis in a two-sample Mendelian randomization 
approach with summary-level exposure of cigarettes per day using Cholinergic Receptor 
Nicotinic Alpha 3 Subunit CHRNA3 (rs1051730 [A])(Liu, et al 2010). We extracted genetic 
summary statistics for CBC from UK Biobank (Bycroft, et al 2018). CBC were measured on 
fresh EDTA whole blood on Beckman Coulter LH750 within 24h of blood draw.  
 
CBC was reported using SI units(Brereton, et al 2016). MPN was defined as any of the 
following: ET, PV, pre-MF, MF, and MPN-U, by ICD coding from registries, WHO coding by 
haematologists, or by bone marrow examination by pathologists(Barbui, et al 2018).  
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Results 
Complete Blood Count 
The Danish General Suburban Population Study (GESUS) 
Characteristics of the study participants based on smoking status are shown in Supplementary 
Table 1. In current smokers, ex-smokers, or ever smokers compared to never smokers, leukocyte 
counts were increased (Figure 1, Supplementary Figures 1-2); results were similar for all 
differential subpopulations, except for NLR and basophils. In current smokers, ex-smokers, or 
ever smokers compared to never smokers, erythrocyte counts were decreased (Figure 1, 
Supplementary Figures 1-2). In current smokers compared to never smokers, haematocrit, 
haemoglobin, MCH, MCV, and RDW were increased (Supplementary Figure 1), but in ex-
smokers, haematocrit and haemoglobin were decreased (Supplementary Figure 2). In current 
smokers, ex-smokers, or ever smokers compared to never smokers, platelet counts and PCT were 
increased (Figure 1, Supplementary Figures 1-2), but MPV and PDW were not different.  
 
Meta-analysis 
For the meta-analysis, we included 92 study populations (including GESUS) on CBC published 
from 1974-2018 comprising 531,741 individuals with 214,703 current smokers, 90,174 ex-
smokers, and 222,600 never or non-smokers between the ages of 15 and 99 years from 33 
countries (Figure 2, Table 1, Supplementary Table 2). Males were overrepresented in the 
meta-analyses with a male:female ratio of 6:1.  
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 Random effects non-standardized weighted mean differences (WMD) in current smokers 
vs. non-smokers per cell type are shown in Supplementary Figures 3-26. The random effects 
SMD of leukocytes in current smokers was 0.82(0.75-0.89, p=2.0*10-108) overall (Figure 3) 
equivalent to a mean difference (WMD) of 1.25*109/L (Supplementary Figure 3). Compared 
with non-smokers, the SMD of leukocytes was 1.56(1.34-1.79, p=7.2*10-41) in current heavy 
smokers, 0.87(0.69-1.05,p=2.2*10-21) in current light smokers, 0.84(0.75-0.93,p=1.1*10-72) in 
current male smokers, and 0.65(0.57-0.73,p=3.5*10-60) in current female smokers 
(Supplementary Figures 27-30). Compared with never smokers, the SMD was 0.16(0.11-0.21, 
p=8.0*10-12) in ex-smokers, and 0.60(0.52-0.68),p=2.2*10-53) in ever-smokers (Supplementary 
Figures 31-32). SMD of absolute counts, but not percentages, for neutrophils, eosinophils, 
basophils, monocytes, and lymphocytes were similar (Figure 3, Supplementary Figures 27-32).  
Random effects SMD of haematocrit in current smokers was 0.53(0.41-0.65, p=6.7*10-19) 
overall (Figure 3) equivalent to a WMD of 0.02 (L/L) (Supplementary Figure 17). Compared 
with non-smokers, the SMD of haematocrit was 1.08(0.77-1.40, p=1.4*10-11) in current heavy 
smokers, 0.54(0.21-0.87,p=1.4*10-3) in current light smokers, 0.29(0.20-0.37,p=3.2*10-11) in 
current male smokers, and 0.33(0.11-0.55,p=3.3*10-3) in current female smokers. Compared 
with never smokers, the SMD was 0.47(0.12-0.82, p=7.8*10-3) in ex-smokers, and 0.19(0.10-
0.28),p=7.3*10-5) in ever-smokers (Supplementary Figures 27-32). Results were similar and in 
the same direction for erythrocytes, haemoglobin, MCH, MCV, and RDW (Figure 3, 
Supplementary Figures 27-32). Results for MCHC and reticulocytes were not consistent 
(Figure 3, Supplementary Figures 27-32). 
Compared with non-smokers, random effects SMD of platelets was 0.04(-0.04-0.13, 
p=0.34) overall in current smokers (Figure 3), 0.22(0.09-0.34, p=5.2*10-4) in current heavy 
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smokers, 0.09(-0.05-0.23,p=0.21) in current light smokers, 0.05 (-0.06-0.16,p=0.40) in current 
male smokers, and 0.01 (-0.14-0.16,p=0.88) in current female smokers. Compared with never 
smokers, the SMD was 0.06 (0.00-0.11, p=0.04) in ex-smokers, and 0.15(0.10-0.19),p=4.6*10-10) 
in ever-smokers (Supplementary Figures 27-32). Random effects SMD of MPV and PDW 
were not significant in any analyses (Figure 3, Supplementary Figures 27-32). 
All analyses presented very high heterogeneity, reflected by the I2 and Q-statistic. 
Egger’s tests for publication bias revealed no publication bias except in analyses of leukocytes 
and platelets in current smokers. Analyses by ethnicity revealed that erythrocyte counts were 
higher in current smokers compared to non-smokers in Middle Eastern countries [SMD(95%CI): 
0.49 (0.12,0.85), p=0.009] whereas erythrocyte counts were lower in current smokers compared 
to non-smokers in Western European countries [SMD(95%CI): -0.23(-0.39,-0.07), p=0.006] (p-
difference=0.02) (Supplementary Table 3); the SMD by ethnicity was not different for 
leukocytes, haematocrit, haemoglobin, or platelets. Analyses by laboratory method did not reveal 
any differences and did not remove heterogeneity (Supplementary Table 4). Meta-regressions 
did not reveal impact of moderator variables (study size, publication year, longitude or latitude of 
study location, or mean ages) (Supplementary Table 5). Leave-one-study-out analyses for 
leukocytes, erythrocytes, haemoglobin, haematocrit, and platelets did not reveal any exaggerated 
influences of studies (Supplementary Tables 6-10). A sub-group analysis of all cell types in 
current smokers vs. never smokers revealed similar but accentuated results compared to analyses 
in current smokers vs. non-smokers (Supplementary Figure 33). 
 
Mendelian randomization study in UK Biobank 
11 
 
The mean(SD) of cigarette smoking per day was 15.5(8.4) in current smokers and 18.9(10.9) in 
ex-smokers. The β(SE) and instrument strength F was [0.0853(0.00439), 376] per SD of 
cigarettes per day for CHRNA3 (rs1051730 [A]). CHRNA (rs1051730[A]) associated with 
chronic obstructive lung disease and lung cancer in UK Biobank (Supplementary Table 11).  
For each rs1051730[A] in CHRNA3 in current smokers, one SD increase in cigarettes per 
day (~10 cigarettes per day) were associated with SD increases in leukocytes of 0.07, neutrophils 
of 0.09, MCH of 0.15, MCV of 0.16, RDW of 0.8, and reticulocytes of 0.07 (Figure 3), with 
results for male higher than in female, and with results persisting but attenuated in ex-smokers 
(Supplementary Figures 34-36). 
 
Meta-analysis of Myeloproliferative Neoplasms 
We included 6 studies, 1,425,529 individuals with 2187 MPN cases (0.2%) (Figure 2, Table 1, 
Supplementary Table 13) published between 1997-2018. The pooled fixed effects odds ratios 
for MPN were 1.44(95%CI: 1.33-1.56;p=1.8*10-19;I2=0%) in current smokers, 1.49(1.26-
1.77;p=4.4*10-6;I-square=0%) in light-smokers, 2.04(1.74-2.39,p=2.3*10-18;I2=51%) in heavy-
smokers vs. non-smokers, and 1.29(1.15-1.44;p=8.0*10-6;I2=0%) in ex-smokers and 1.39(1.30-
1.48,p=8.3*10-23;I2=35%) in ever smokers vs. never-smokers (Figure 5 and 6). There was no 
evidence of publication bias. Subgroup analyses for PV and ET showed similar results for 
current smokers, which had overlapping confidence intervals with ex-smokers and ever-smokers; 
there were only two studies including patients with primary MF (Supplementary Table 14). 
 
Discussion   
12 
 
We examined the association between smoking, blood counts, and risk of MPN in 2.3 million 
participants. In the Danish population study and in the meta-analysis, current smoking was 
associated with increased leukocyte counts (including, neutrophils, eosinophils, monocytes, 
lymphocytes), haematocrit, haemoglobin, MCH, and MCV, and increased risk of MPN 
compared with non-smokers. Leukocyte counts were impacted the most relative to other cell 
types. Compared to non-smokers, there was a dose-trend for cell counts, indices, and MPN for 
ever/ex-/current smokers and light/heavy smokers, and male/female smokers. All analyses for 
CBC presented high between-study heterogeneity but low publication bias, whereas analyses for 
MPN presented low to moderate between-study heterogeneity with no publication bias. In the 
MR study, higher cigarette consumption in current smokers was associated with increased 
leucocytes, neutrophils, MCH, MCV, RDW, and reticulocytes. 
The chemical compounds found in tobacco, such as nicotine, tar, carbon monoxide, and 
hydrogen cyanide, are associated with genotoxic, cytotoxic and cancerogenic effects(Lohler and 
Wollenberg 2019). Thus, the observed associations between smoking and increased CBCs could 
merely reflect production of cells in reaction and secondary to smoking in an otherwise healthy 
cell lineage. It could also reflect acquired mutations in hematopoietic stem cells in the bone 
marrow with clonal hematopoiesis of indeterminate potential or MPN, as the associations 
persisted despite smoking cessation (Baxter, et al 2005, Nielsen, et al 2013, Weinberg, et al 
2012). 
Smoking and MPNs share several clinical, biochemical and molecular characteristics, 
which may all be mediated by chronic inflammation and oxidative stress(Hasselbalch 2015). 
Smoking is associated with genotoxic effects, namely the acquired somatic driver mutation JAK2 
V617F for MPN(Baxter, et al 2005, Nielsen, et al 2013, Weinberg, et al 2012), and oxidative 
13 
 
damage to DNA leading to increased reactive oxygen species(Prieme, et al 1998). The JAK-
STAT and NF-κB signaling pathways, associated with carcinogenesis, are activated and 
perpetuated by reactive oxygen species in both smokers and in patients with MPNs(Bjorn and 
Hasselbalch 2015, Hasselbalch 2015). Smokers, as well as patients with MPN, have a high risk 
of thrombosis, which is likely explained by an elevated haematocrit and leukocytosis and in vivo 
leukocyte, platelet and endothelial activation(Hasselbalch 2015, Spivak 2017). Interestingly, 
patients with MPNs have increased risk of secondary cancers, particularly lung cancer and 
urinary tract cancers, which are also related to smoking(Frederiksen, et al 2011, Landtblom, et al 
2018).   
Some CBC results were discordant in the general population study, the meta-analysis, 
and the MR study. In both the MR study and the general population study, current smoking was 
inversely associated with erythrocyte counts, but in the meta-analysis current smoking associated 
with increased erythrocyte counts. There can be several explanations for these findings. First, 
smoking is associated with hypoxia as carbon monoxide binds to haemoglobin and thereby 
reduces the oxygen-binding capacity which theoretically would lead to increased erythrocytes as 
a compensatory mechanism(Goldstein 2008). Second, the lower counts of erythrocytes in current 
smokers compared to non-smokers observed in the general population study along with an 
increased heterogeneity in red cell size (RDW) could be caused by a decreased erythropoiesis, 
increased cell destruction, bone marrow depression, and chronic inflammation(Asgary, et al 
2005, Li, et al 2017). Third, the inverse relationship between smoking and erythrocyte counts 
could also be explained by chronically ill smokers being less likely to participate. Fourth, in a 
recent MR study, smoking was associated with increased leukocytes, haematocrit, haemoglobin, 
and MCV, but not erythrocytes or platelets(Pedersen, et al 2019). 
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In GESUS and the meta-analysis, current smoking was associated with increased MCV 
(i.e. macrocytosis) and RDW, and likewise in the MR study, the smoking intensity was 
associated with increased MCV and RDW in current smokers. The findings for MCV can be 
explained by smoking and cotinine, a nicotine metabolite, also being associated with decreased 
levels of folate and cobalamin and increased levels of homocysteine(Haj Mouhamed, et al 2011). 
An increased RDW is associated with poor overall survival and poor cancer-specific survival in 
patients with cancer(Hu, et al 2017), particularly in patients with CML(Iriyama, et al 2015), but 
no studies have investigated RDW as a prognostic factor for MPN. 
For CBC, the SMD allowed us to compare all cell types on the same scale, and the 
random effects statistic accounted for the high heterogeneity in study designs across studies. We 
investigated study characteristics such as smoking intensity (heavy vs. light), smoking status 
(current, ex, ever), sex, lab testing methodology, study size, year published, age distribution, or 
geographical region as culprits for heterogeneity. In the meta-analysis, we were not able to 
address pack-years, smoking duration, years since smoking cessation, or differences between 
filter vs. non-filter cigarettes, as reporting in studies were too diverse or lacking on these factors. 
A recent study showed that within ex-smokers, years since smoking cessation was inversely 
associated with white blood cells and the differentials, but values were still elevated compared to 
never smokers(Pedersen, et al 2019). Lastly, many unreported pre-analytical factors in the 
studies in the meta-analyses may have affected CBC such as seasonal and diurnal variations, 
fasting vs. non-fasting sampling, time since last cigarette smoked, position at blood draw (supine 
or sitting), altitude, physical activity, possible dormant infections, allergies, undiagnosed 
diseases, nutritional status, menstrual cycle and menopausal status.  
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For MPN, there was not enough information to address sex differences. Also, the 
description of MPN was not completely identical in the studies. Leal used international 
classification of diseases 9 (ICD-9)(Leal, et al 2014) and Pedersen ICD-8 and ICD-10(Pedersen, 
et al 2018). Sørensen recruited MPN patients from a single-institution based on WHO-5 MPN 
criteria(Lindholm Sorensen and Hasselbalch 2016). Kroll used ICD-10 and other classification 
systems and included myelodysplastic syndrome, CML, and other myeloproliferative 
disorders(Kroll, et al 2012), but it was not possible to filter out these diagnoses. Pasqualetti did 
not specify the MPN diagnosis or coding any further (Pasqualetti, et al 1997). None of the 
studies explicitly mentioned bone marrow pathology as part of the MPN diagnosis. Incidence 
rates (IR per 100,000 person-years) of MPN varied across the follow-up studies with an IR of 98 
in Leal (Leal, et al 2014) with a median of 11 years of follow-up ( ~ 8.9 annually per 100,000), 
an IR of 13 in Pedersen with a mean of 6.8 years of follow-up ( ~ 1.9 annually per 100,000) 
(Pedersen, et al 2018), and an IR of 16 in Kroll with a mean of 10 years of follow-up ( ~1.6 
annually per 100,000)(Kroll, et al 2012). In comparison, a recent meta-analysis reported an 
incidence rate of 2.6 annually per 100,000 for MPN(Titmarsh, et al 2014). 
In conclusion, the association of smoking with hyperproliferation of blood cells and MPN 
were supported by the strength of the associations, the consistency across the large number of 
observational studies, the MR analysis, and the dose-response relationship. Furthermore, 
previous complementary studies support the mechanistic specificity of smoking with 
genotoxicity forgoing and being the driver of MPN. Future studies should elucidate when 
increased cell counts are merely secondary to smoking or reflect an underlying cancer. Our 
findings of an association between smoking and MPNs should alert clinicians that elevated cell 
counts in smokers may also reflect an underlying myeloproliferative cancer. 
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*Total individuals included were the sum of current smokers, ex-smokers, non-smokers, and never-
smokers. If articles did not provide N for exposed/unexposed, total individuals were the number listed 
as total in the article. 
**The meta-analysis of blood counts included GESUS. Never-smokers were life-long never-smokers. 
Non-smokers were non-current smokers. Men+women does not add up to total individuals, as some 
studies did not provide information on sex. 
#UK biobank genotypes from Haplotype Reference Consortium (HRC) plus UK10K & 1000 Genomes 
reference panels as released by UK Biobank in March 2018. See text for details. Never smokers is 
approximately 49% of total, but the exact number for those with genotype+hematology was not 
publically available. 
##Heavy  smokers:  >=20 cigarettes per day. Light-smokers <20 cigarettes per day. 
GESUS: The Danish General Suburban Population Study. MPN: myeloproliferative neoplasms. UK:   
United Kingdom. 
 
 
 
Table 1. Characteristics of study designs on chronic cigarette smoking, complete blood count, and MPN
Complete blood counts MPN All
General population
(A)
Meta-analysis**
(B)
Mendelian 
Randomization (C) 
Meta-analysis
(D) (B+C+D)
Study populations GESUS 92 UK Biobank# 6
Countries Denmark 33 UK 5
Publication years (yyyy-yyyy) - 1974-2018 2018 1997-2018
Age range, years 20-99 15-99 40-69 16-99
Individuals, N* 11083 531741 350475 1425529 2307745
Men, N 5155 454003 162399 31377 647779
Women, N 5928 77252 188076 1391966 1657294
Current smokers, N 2217 214703 25348 267942 507993
Current heavy smokers, N 690 11881 - 5729 17610
Current light smokers, N 1371 22527 - 5088 27615
Ex-smokers, N 3933 90174 84456 380672 555302
Ever-smokers, N 6150 243969 109804 648614 1002387
Non-smokers, N - 68840 - 671714 740554
Never-smokers, N 4933 153760 171500 - 325260
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Figure Legend  
Figure 1. Standardized adjusted mean differences in current smokers vs. never smokers – 
The Danish General Suburban Population Study  
Figure 2. PRISMA flow chart. EMBASE: Excerpta Medica database. GESUS: The Danish 
General Suburban Population Study. WHO-GHL: World Health Organization Global Health 
Library. 
Figure 3. Meta-analyses of complete blood cell counts - Current smokers vs non-smokers  
Figure 4. Mendelian Randomization using CHRNA3 genotype in UKBiobank – SD increase 
in complete blood cell counts per genetically one SD increase in cigarettes per day in 
current smokers. CHRNA: Cholinergic Receptor Nicotinic Alpha 3 Subunit (rs1051730 [A]). 
SMD: standardized mean difference (adjusted for sex, age, principal components). 
Figure 5. Meta-analysis of Philadelphia-negative myeloproliferative neoplasms – Current 
smokers vs. non-smokers. 
Figure 6. Meta-analyses of Philadelphia-negative chronic myeloproliferative neoplasms – 
By smoking status. P-Egger: publication bias p-value according to Eggers test. p-het: 
heterogeneity p-value. SMD: standardized mean difference.  
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